Quoin Pharmaceuticals (NASDAQ:QNRX) vs. Aurinia Pharmaceuticals (NASDAQ:AUPH) Head to Head Contrast

Quoin Pharmaceuticals (NASDAQ:QNRX) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, risk, profitability, analyst recommendations and dividends.

Profitability

This table compares Quoin Pharmaceuticals and Aurinia Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-535.00%	-223.99%
Aurinia Pharmaceuticals	101.46%	27.47%	19.61%

Earnings & Valuation

This table compares Quoin Pharmaceuticals and Aurinia Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81 million	($34.29)	-0.19
Aurinia Pharmaceuticals	$283.05 million	7.07	$287.20 million	$2.08	7.40

Aurinia Pharmaceuticals has higher revenue and earnings than Quoin Pharmaceuticals. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

8.6% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 13.5% of Quoin Pharmaceuticals shares are held by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Quoin Pharmaceuticals and Aurinia Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1	0	0	0	1.00
Aurinia Pharmaceuticals	0	4	2	0	2.33

Aurinia Pharmaceuticals has a consensus price target of $17.25, indicating a potential upside of 12.09%. Given Aurinia Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Aurinia Pharmaceuticals is more favorable than Quoin Pharmaceuticals.

Volatility and Risk

Quoin Pharmaceuticals has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.

Summary

Aurinia Pharmaceuticals beats Quoin Pharmaceuticals on 11 of the 13 factors compared between the two stocks.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.